Teriparatide Treatment for Osteoporosis

Assessment and Indications

The American College of Rheumatology conditionally recommends teriparatide over anti-resorptives only in patients at very high risk of fracture 1
Teriparatide is typically reserved for patients with severe osteoporosis with documented fractures, very high fracture risk who have failed or cannot tolerate first-line therapies, or glucocorticoid-induced osteoporosis at very high risk of fracture 1, 2, 3
Elevated ALP with normal to low calcium levels requires further investigation for underlying causes before considering teriparatide therapy 3, 4

Before considering teriparatide, the following assessments are required: bone mineral density (BMD) testing with DEXA scan, fracture risk assessment using FRAX tool for patients over 40, vertebral imaging with VFA or spinal X-ray, evaluation for secondary causes of osteoporosis, and complete metabolic workup including vitamin D levels 1, 2, 3
First-line management should include complete evaluation of the elevated ALP to determine its source, assessment of vitamin D status, DEXA scan to determine bone mineral density, and if osteoporosis is confirmed, oral bisphosphonates would be the first-line therapy 2, 3, 4

Calcium and vitamin D supplementation should be optimized based on laboratory values 1
If the patient has confirmed osteoporosis with high fracture risk and bisphosphonates are contraindicated, only then would teriparatide be considered 1, 2
The current clinical information provided is insufficient to warrant teriparatide therapy, and further diagnostic workup is needed to determine the cause of back pain and elevated ALP before considering any osteoporosis-specific therapy 1, 2, 3, 4

The American Academy of Family Physicians recommends daily dietary allowances for calcium of 1,000-1,200 mg and for vitamin D of 600-800 IU for adults with osteoporosis 5
Teriparatide is typically used in patients with severe osteoporosis or who have had fractures, and is generally considered a second-line therapy after bisphosphonates in most treatment algorithms 5
For adults with very high fracture risk, teriparatide may be preferred over anti-resorptive agents (bisphosphonates or denosumab) 6

The National Comprehensive Cancer Network recommends avoiding use of teriparatide in patients with cancer or history of malignancy prone to metastasize to bone, and using with caution in patients with increased risk of osteosarcoma 7

In glucocorticoid-induced osteoporosis, teriparatide is recommended after oral bisphosphonates when they are not appropriate, as suggested by the American College of Rheumatology 8

The Congress of Neurological Surgeons (2021) provides Grade B evidence that clinicians should consider preoperative teriparatide in osteoporotic patients undergoing spinal instrumentation to decrease postoperative adverse events, with teriparatide reducing screw loosening (7% vs 13% with bisphosphonates) and improving fusion rates (82% vs 68%) 9, 10, 11
In perioperative spine surgery, Level II evidence demonstrates teriparatide superiority over bisphosphonates for earlier fusion (8 months vs 10 months), higher fusion rates at interim timepoints, reduced pedicle screw loosening, and faster BMD recovery 9, 10, 11, 12, 13, 14, 15
The American College of Rheumatology conditionally recommends teriparatide over anti-resorptives only in patients at very high fracture risk, representing a hierarchical approach where bisphosphonates remain first-line for most patients, although the specific recommendation is not cited here, the Congress of Neurological Surgeons recommends teriparatide in patients undergoing spinal instrumentation 9, 16

The American College of Physicians recommends teriparatide as a second-line or third-line anabolic therapy for patients with severe osteoporosis at very high fracture risk, particularly those who have failed or cannot tolerate bisphosphonates, or who have sustained fractures despite antiresorptive therapy 17
Postmenopausal women with severe osteoporosis who have documented vertebral or non-vertebral fractures, particularly those occurring despite adequate bisphosphonate therapy, should be considered for teriparatide treatment 18, 19, 17
Patients at very high fracture risk, defined by T-score ≤ -3.5, multiple prevalent fractures, or fractures on therapy, are eligible for teriparatide therapy 17
The European League Against Rheumatism recommends teriparatide for glucocorticoid-induced osteoporosis in patients at high fracture risk or intolerant to bisphosphonates 20
Calcium supplementation of 1,000-1,200 mg daily and vitamin D supplementation of 600-800 IU daily are recommended for patients on teriparatide therapy 18, 20

The National Comprehensive Cancer Network recommends avoiding teriparatide in patients with open epiphyses, Paget's disease of bone, bone metastases, or history of skeletal malignancies 18, 19
Patients with prior external beam or implant radiation therapy involving the skeleton should not receive teriparatide 18, 19
The risk of osteosarcoma is a concern, although a study of 200,000 patients demonstrated no significant difference in osteosarcoma incidence between treated patients and the general population 18, 19

The maximum treatment duration with teriparatide is 2 years during a patient's lifetime, unless the patient remains at or returns to very high fracture risk 17
Generic bisphosphonates should be prescribed as first-line therapy when possible, as teriparatide is significantly more expensive 17